<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ganga Pharmaceuticals Limited has filed its annual disclosure with BSE confirming that it does not qualify as a 'Large Corporate' under SEBI circulars dated November 26, 2018 and October 19, 2023, for the financial year ended March 31, 2025. The company's total outstanding borrowings stand at approximately Rs. 1.42 crore (Rs. 1,42,12,851) as on March 31, 2025, which falls well below the threshold required for Large Corporate classification. The disclosure was signed by Managing Director Bharat Brijmohan Sharma and CFO Anagh Bharat Sharma on April 22, 2025. BSE is identified as the stock exchange where any shortfall-related fine would have been payable, had the company been classified as a Large Corporate.
This is a routine regulatory compliance filing with no material impact on shareholders or stock price. It simply confirms the company's small scale of borrowings relative to SEBI's Large Corporate thresholds.